Our passion for innovation

Ncardia believes that stem cell technology helps bring better medicines to patients faster. We develop, produce and commercialize highly-predictive human cellular (disease) assay systems for safety and efficacy testing aiming to accelerate and improve drug candidate selection, reduce costs and ultimately increase drug discovery and development efficiency.


hiPSC solutions for Drug Discovery

Ncardia provides a broad portfolio of cardiovascular and neural iPSC services for safety and efficacy testing and analysis. Our DiscoverHIT Screening Platform provides a flexible solution for bringing hiPSC disease models into predictive assays suitable for drug discovery (screening) campaigns.The safety services are pre-configured service packages based on electrophysiology, biochemistry and contraction assay technology for predictive safety pharmacology and toxicology testing.


iPSC Manufacturing Platform

Ncardia is an iPSC-dedicated service organization with over a decade of experience in the development and commercial manufacture of iPSC-derived cardiovascular and CNS cell models. We also have expertise in a broad range of additional cell lineages, making Ncardia well positioned to enable Cell and Gene therapy developers to create therapeutic cells to specification.


We are ready to help

Ncardia is committed to delivering a tailor-made solution to address our client's needs. We combine expertise in differentiated cardiovascular and neuronal iPSC-derived cell model production with laboratories equipped specially for stem cell applications. Our scientists provide expertise in disease modeling, assay development, iPSC manufacturing and compound screening for drug efficacy and safety pharmacology.